UK markets closed

Zealand Pharma A/S (22Z.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
17.37-0.74 (-4.09%)
As of 09:09AM CET. Market open.
Full screen
Previous close18.11
Open17.42
Bid16.52 x 60000
Ask17.02 x 60000
Day's range17.37 - 17.42
52-week range17.18 - 30.34
Volume22
Avg. volume2
Market cap750.657M
Beta (5Y monthly)1.08
PE ratio (TTM)N/A
EPS (TTM)-3.55
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est222.65
  • Zacks

    Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study

    Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.

  • Globe Newswire

    Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

    Company announcement – No. 3 / 2022 Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Full trial results of EASE-SBS 1 expected in the third quarter of 2022Pending positive pivotal data, Zealand intends to file for marketing approval with the U.S. Food and Drug Administration Copenhagen, DK and Boston, MA, U.S. January 20, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the

  • Globe Newswire

    Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022

    Company announcement – No. 2 / 2021 Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022 Copenhagen, DK and Boston, MA, January 19, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareho